- Q1 2024 Verrica Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2024€7.31 (+1.81%)Earnings
- Q4 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptFeb 29, 2024€5.15 (-0.96%)Earnings
- Q3 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023€3.04 (-10.59%)Earnings
- Verrica Pharmaceuticals Inc to Host KOL Event (Virtual) TranscriptOct 11, 2023
- Verrica Pharmaceuticals Inc to Discuss FDA Approval of YCANTH Call TranscriptJul 24, 2023
- Verrica Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Verrica Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 17, 2023
- Verrica Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Verrica Pharmaceuticals Inc VIRTUAL PANEL: The Pursuit of Molluscum - Beetlejuice and Nobel Prizes TranscriptSep 22, 2020
Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon. Thank you for joining us at the H.C. Wainwright 24th Annual Global Investment hybrid conference. My name is Oren Livnat. I'm specialty pharmaceuticals analyst here at H.C. Wainwright. And it's my pleasure to welcome for a brief chat today Ted White, CEO and President of Verrica Pharmaceuticals. I do cover Verrica with a buy rating. So afterwards and separately, feel free to reach out to me with any questions.
Verrica is a medical dermatology-focused company with a lead asset, VP-102, a topical cantharidin drug device combination to treat molluscum contagiosum lesions. It's a highly prevalent contagious condition with no FDA-approved treatments.
And exciting times, Verrica's in the homestretch, already under FDA review, and we expect approval next year. So it's about to be a commercial story and right in my spec pharma wheelhouse. So, Ted, welcome.
Thank you, Oren. Good to be with you.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)